Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure

Clinical Microbiology and Infection

Volumn 10, Issue 2, 2004, Pages 119-126

  Sune C ^a   Brennan, L ^a   Stover, D R ^b   Klimkait, Thomas ^a,c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b MDS Proteomics Inc   (United States)

^c InPheno AG   (Switzerland)

Author keywords

Fitness; HIV; Polymorphisms; Protease inhibitors; Resistance

Indexed keywords

AMINO ACID; GAG PROTEIN; INDINAVIR; PROTEIN P55; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR;

ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; KINETICS; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; VIRUS MUTANT; VIRUS REPLICATION; WILD TYPE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 1342290276     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.00832.x     Document Type: Article

References (35)

1. Ho DD, Neumann AD, Perelson AS et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126.
2. Wei X, Ghosh SK, Taylor ME et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-122.
3. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242: 1168-1171.
4. Najera I, Holguin A, Quiñones-Mateu ME et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995; 69: 23-31.
5. Kozal MJ, Shah N, Shen N et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996; 2: 753-759.
6. Perno CF, Cozzi-Lepri A, Balotta C et al. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 2001; 184: 983-991.
7. Lech WJ, Wang G, Li Yan YL et al. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996; 70: 2038-2043.
8. Pieniazek D, Rayfield M, Hu DJ et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease-naive individuals worldwide. AIDS 2000; 14: 1489-1495.
9. Cane PA, de Ruiter A, Rice P et al. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom. J Clin Microbiol 2001; 39: 2652-2654.
10. Holguín A, Álvarez A, Soriano V. High prevalence of subtype G and spectrum of natural polymorphisms at the protease gene among HIV-infected immigrants attended in Madrid. AIDS 2002; 16: 1163-1170.
11. Vergne L, Peeters M, Mpoudi-Ngole E et al. Genetic diversity of protease and reverse transcriptase sequences in non-B HIV type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000; 38: 3919-3925.
12. Markowitz M, Mo H, Kempf DJ et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995; 69: 701-706.
13. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999; 73: 3744-3752.
14. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Loss of viral fitness associated with multiple gag and gagpol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998; 72: 3300-3306.
15. Rose RE, Gong YF, Greytok JA et al. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci USA 1996; 93: 1648-1653.
16. Borman AM, Paulous S, Clavel F. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol 1996; 77: 419-426.
17. Mammano F, Trouplin V, Zennou V, Clavel F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and presence of drug. J Virol 2000; 74: 8524-8531.
18. Klimkait T, Stauffer F, Lupo E, Sonderegger-Rubli C. Dissecting the mode of action of various HIV-inhibitor classes in a stable cellular system. Arch Virol 1998; 143: 2109-2131.
19. Jacobsen H, Yasargil K, Winslow DL et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995; 206: 527-534.
20. Condra JH, Schleif WA, Blahy OM et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569-571.
21. Kohl NE, Emini EA, Schleif WA et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85: 4686-4690.
22. Maschera B, Darby G, Palu G et al. Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J Biol Chem 1996; 271: 33231-33235.
23. Croteau G, Doyon L, Thibeault D et al. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997; 71: 1089-1096.
24. Deeks SG. Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure. JAMA 2001; 286: 224-226.
25. Lorenzi P, Opravil M, Hirschel B et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999; 13: F17-F21.
26. Ruiz L, Martinez-Picado J, Romeu J et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 2000; 14: 397-403.
27. Izopet J, Massip P, Souyris C et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 2000; 14: 2247-2255.
28. Miller V, Sabin C, Hertogs K et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14: 2857-2867.
29. Wilson SI, Phylip LH, Mills JS et al. Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition. Biochem Biophys Acta 1997; 1339: 113-125.
30. Martinez-Picado J, Savara AV, Shi L, Sutton L, D'Aquila RT. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2000; 275: 318-322.
31. Nijhuis M, Schuurman R, de Jong D et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999; 13: 2349-2359.
32. Jacobsen H, Hanggi M, Ott M et al. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis 1996; 173: 1379-1387.
33. Eastman PS, Mittler J, Kelso R et al. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol 1998; 72: 5154-5164.
34. Blaak H, Brouwer M, Ran LJ, Wolf F, Schuitemaker H. In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J Infect Dis 1998; 177: 600-610.
35. Quiñones-Mateu ME, Ball SC, Marozsan AJ et al. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol 2000; 74: 9222-9233.